Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03883633 · ClinicalTrials.gov registry record
Reversal of Cognitive Decline (ReCODE) Study
A clinical trial, sponsored by QuesGen Systems.
- Completed
- Registry status
- 30
- Enrollment target
NCT03883633: Completed study, sponsored by QuesGen Systems.
NCT03883633 is a clinical trial that has completed, run by QuesGen Systems. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03883633 has completed, sponsored by QuesGen Systems.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Prospective study on patients enrolled in the ReCODE treatment protocol
Primary Outcome
Participants will be given an on-line assessment to test memory and recall using CNS (Central Nervous System) Vitals assessment.
Interventions
- BEHAVIORAL ReCODE Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-06-30 |
| Est. Completion | 2020-12-31 |
What the finished NCT03883633 record still lists
NCT03883633 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ReCODE Protocol is the first listed.
NCT03883633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03883633 about?
NCT03883633 is a clinical study titled "Reversal of Cognitive Decline (ReCODE) Study". Prospective study on patients enrolled in the ReCODE treatment protocol
What is the current status of trial NCT03883633?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2019-06-30. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03883633?
The interventions under investigation include: ReCODE Protocol (BEHAVIORAL).
Who is sponsoring clinical trial NCT03883633?
This trial is sponsored by QuesGen Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI